# Isomorphic Labs **Source:** https://geo.sig.ai/brands/isomorphic-labs **Vertical:** Healthcare & Life Sciences **Subcategory:** AI Drug Discovery **Tier:** Emerging **Website:** isomorphiclabs.com **Last Updated:** 2026-04-14 ## Summary Alphabet/DeepMind drug discovery spinoff raised $600M from Thrive Capital; Drug Design Engine doubled AlphaFold3 accuracy for molecular design; partnering with major pharma; preparing first clinical trials from AI-directed drug pipeline across multiple therapeutic areas. ## Company Overview Isomorphic Labs is an Alphabet company spun out of Google DeepMind to apply AI to the full drug discovery pipeline, from target identification through molecular design and clinical candidate selection. Founded in 2021 under CEO Demis Hassabis's vision of using AI to accelerate medicine, Isomorphic operates with the scientific resources and computational infrastructure of DeepMind while functioning as a standalone drug discovery organization. The company's founding mission is to use AI not merely as a tool to assist drug hunters, but as the primary engine of drug design — replacing the slow, expensive, and largely empirical process of traditional medicinal chemistry with AI-directed molecular engineering.\n\nIsomorphic's core platform is the Drug Design Engine, a proprietary AI system built on top of AlphaFold architecture. The Drug Design Engine has achieved landmark performance results, reportedly doubling the accuracy of AlphaFold3 at predicting how small molecules bind to their protein targets — the fundamental problem in structure-based drug design. This capability enables Isomorphic to computationally design molecules predicted to bind their targets with far greater precision than conventional methods, potentially eliminating many of the expensive iterative cycles that make drug development so slow. The company has also established major pharma partnerships with Eli Lilly and Novartis to co-develop drug candidates across multiple therapeutic areas.\n\nIsomorphic raised $600M from Thrive Capital in 2024–2025, bringing substantial private capital alongside its Alphabet backing to accelerate pipeline development. As of 2026, the company is preparing for its first clinical trials — a critical milestone that will test whether its computational drug design predictions translate into human efficacy. With AlphaFold-derived technology at its core, partnerships with two of the world's largest pharmaceutical companies, and over half a billion in funding, Isomorphic Labs represents the most credentialed and well-resourced pure-play AI drug discovery company in existence. ## Frequently Asked Questions ### What is Isomorphic Labs? Alphabet/DeepMind spinoff using AlphaFold tech for AI drug discovery and design. ### How much has it raised? $600M from Thrive Capital in March 2025 (first external funding). ### What is IsoDDE? Drug Design Engine (Feb 2026) doubling AlphaFold 3's protein-ligand prediction accuracy. ### How does Isomorphic Labs use AlphaFold for drug discovery? Isomorphic Labs extends AlphaFold's protein structure prediction capabilities into drug design — using AI to predict not just how proteins fold, but how drug molecules interact with protein binding sites, predict binding affinity, and design novel molecular structures with desired pharmacological properties. ### What pharmaceutical partnerships has Isomorphic Labs signed? Isomorphic Labs signed landmark drug discovery partnerships with Eli Lilly (worth up to $1.7B) and Novartis (worth up to $1.2B) in 2024, applying its AI platform to multiple drug programs across oncology and other therapeutic areas. These deals represent some of the largest AI drug discovery collaborations ever signed. ### What is AlphaFold 3 and what did it unlock for Isomorphic Labs? AlphaFold 3, released by DeepMind in 2024 and co-developed with Isomorphic Labs, extended the original protein structure prediction to model interactions between proteins, DNA, RNA, and small molecule drugs. This made AlphaFold 3 directly applicable to drug design rather than just structural biology research. ### How does Isomorphic Labs differ from other AI drug discovery companies? Isomorphic Labs' core advantage is its direct lineage from DeepMind's AlphaFold research — the most validated AI system in structural biology. Unlike competitors who license or adapt published models, Isomorphic Labs develops next-generation AI architectures internally with Alphabet's computing resources and research talent. ### Does Isomorphic Labs develop its own drug pipeline? Isomorphic Labs operates both a partnership model (applying its platform to partners' programs) and is developing its own internal drug pipeline in selected therapeutic areas. As an Alphabet company with access to significant capital, it can afford to run internal programs alongside its commercial partnerships. ### What is Isomorphic Labs? Isomorphic Labs is a DeepMind spin-out applying AI to drug discovery — leveraging the breakthrough AlphaFold protein structure prediction technology and building additional AI systems to accelerate small molecule drug development. ### What is the relationship between Isomorphic Labs and DeepMind? Isomorphic Labs was spun out from Alphabet (Google's parent) as an independent company in 2021 to commercialize DeepMind's AI capabilities in life sciences — it retains deep connections to DeepMind's research team and technology. ### What pharmaceutical partnerships has Isomorphic Labs formed? Isomorphic Labs signed landmark drug discovery deals worth up to $3B with Eli Lilly and Novartis in 2024 — among the largest AI drug discovery partnerships announced, validating AI-native approaches to pharmaceutical development. ### How does AlphaFold benefit Isomorphic Labs's drug discovery? AlphaFold's ability to predict protein 3D structures from amino acid sequences gives Isomorphic Labs deep structural insight into drug targets — enabling structure-based drug design at unprecedented scale and speed. ### What is Isomorphic Labs's long-term vision? Isomorphic Labs aims to make drug discovery faster, cheaper, and more successful by applying AI across the entire development pipeline — from target identification through clinical prediction — potentially transforming a $2T+ industry. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*